Dualitas Therapeutics Appoints Karim Dabbagh as Chief Executive Officer to Advance Novel Bispecific Antibody Pipeline Toward the Clinic

Dualitas Therapeutics Appoints Karim Dabbagh as Chief Executive Officer to Advance Novel Bispecific Antibody Pipeline Toward the Clinic

PR Newswire

SOUTH SAN FRANCISCO, Calif., June 8, 2026

Karim Dabbagh, Ph.D., joins as CEO, bringing leadership experience in advancing immunology and inflammation therapies through clinical trials; Rich Murray, Ph.D., former interim CEO, remains on the Board of DirectorsDualitas announces the nomination of DTX-102 as its lead development candidate, a bispecific antibody powered by a novel immune proximity engager mechanism, for the treatment of rheumatoid arthritis; clinical studies are anticipated to begin in 2027Dualitas announces two additional preclinical programs – enabled by its proprietary proximity engager – across large population indications including allergy, dermatology and gastrointestinal diseasesSOUTH SAN FRANCISCO, Calif., June 8, 2026 /PRNewswire/ -- Dualitas Therapeutics, Inc., a biotechnology company developing next-generation bispecific antibody therapies for immunology and inflammation ("I&I") indications, has appointed Karim Dabbagh, Ph.D., as chief executive officer to lead the company as it advances its lead development candidate, DTX-102, a bispecific antibody incorporating Dualitas' immune proximity engager, for autoimmune indications including rheumatoid arthritis. IND-enabling studies have begun for DTX-102 and it is anticipated to enter the clinic in 2027.